ABBV vs KO: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Coca-Cola Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
AbbVie Inc. · Healthcare
$197.69
+11.0% upside to fair value
Grade C
High Quality
VS
The Coca-Cola Company · Consumer Defensive
$78.19
-7.8% upside to fair value
Grade D
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+11.0%).
KO trades at a lower forward P/E
(24.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
KO |
| Current Price |
$197.69 |
$78.19 |
| Fair Value Estimate |
$219.51 |
$72.12 |
| Upside to Fair Value |
+11.0%
|
-7.8%
|
| Market Cap |
$349.7B |
$336.5B |
| Forward P/E |
83.3x
|
24.6x
|
| EV / EBITDA |
23.4x
|
19.9x
|
| Price / Sales |
5.7x
|
6.8x
|
| Price / FCF |
18.7x
|
26.8x
|
| Revenue Growth YoY |
+10.0%
|
+12.1%
|
| Gross Margin |
70.2%
|
61.7%
|
| Operating Margin |
26.7%
|
29.3%
|
| Return on Equity |
-361.6%
|
43.6%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
3.73%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
The Coca-Cola Company is a leading global beverage company specializing in non-alcoholic drinks with a diversified portfolio including sparkling soft drinks, juices, water, coffee, and energy beverages. The business quality is high due to its durable brand moat, consistent earnings growth, and strong operational efficiency, reflected in a 43.6% return on equity and 12.1% revenue growth in the mos…
Accumulation Zones
| Metric |
ABBV |
KO |
| Zone Low |
$164.63 |
$54.09 |
| Zone High |
$186.58 |
$61.30 |
| In Buy Zone? |
No
|
No
|